Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2025)

Amylyx Pharmaceuticals has reported Cash from Financing Activities over the past 5 years, most recently at -$208000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$208000.0 for Q4 2025, down 289.09% from a year ago — trailing twelve months through Dec 2025 was $257.0 million (up 73758.91% YoY), and the annual figure for FY2025 was $257.0 million, up 73758.91%.
  • Cash from Financing Activities for Q4 2025 was -$208000.0 at Amylyx Pharmaceuticals, down from $191.6 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for AMLX hit a ceiling of $232.2 million in Q4 2022 and a floor of -$1.1 million in Q4 2021.
  • Median Cash from Financing Activities over the past 5 years was $889000.0 (2023), compared with a mean of $44.8 million.
  • Peak annual rise in Cash from Financing Activities hit 239407.5% in 2025, while the deepest fall reached 289.09% in 2025.
  • Amylyx Pharmaceuticals' Cash from Financing Activities stood at -$1.1 million in 2021, then surged by 21899.25% to $232.2 million in 2022, then crashed by 99.9% to $230000.0 in 2023, then plummeted by 52.17% to $110000.0 in 2024, then tumbled by 289.09% to -$208000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were -$208000.0 (Q4 2025), $191.6 million (Q3 2025), and -$31000.0 (Q2 2025) per Business Quant data.